Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
Date:3/4/2008

RICHMOND, Va., March 4 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq CM: INSM), a developer of follow-on biologics and biopharmaceuticals, today reported results for the quarter and full-year ended December 31, 2007.

Full-Year 2007 and Recent Company Highlights

-- Follow-on Biologics Program

-- Completed development of INS-19 (Granulocyte Colony Stimulating

Factor or G-CSF) and INS-20 (Peg G-CSF), positioning these

products to enter clinical trials in 2008;

-- Testified at two congressional hearings - "Safe and Affordable

Biotech Drugs - The Need for a Generic Pathway" and "Assessing the

Impact of a Safe and Equitable Biosimilar Policy in the United

States" where Geoffrey Allan, Ph.D., the Company's President and

CEO, urged the need to create a regulatory pathway for the

approval of follow-on biologics ("FOBs") in the U.S.;

-- Appointed Steve Glover, who has approximately 25 years of

biotechnology experience, as President of the Company's FOB

program in order to most effectively leverage Insmed's scientific

capabilities in the field;

-- Completed external market assessment using a major U.S. market

research firm, which indicated a $9 billion annual market

potential for the Company's FOB candidates whose corresponding

innovator products' patents expire within the next eight years;

-- Launched a broad education campaign on the importance of

establishing a regulatory pathway for FOBs in the U.S.; and

-- Commissioned econometric study by economist Dr. Robert J. Shapiro,

former Under Secretary of Commerce in the Clinton Administration,

that identified potential cost savings of approximately $378

billion over the next 20 years from making FOBs a
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
2. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
3. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed to Appeal Delisting Notification From Nasdaq
6. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
7. Insmed Appoints Dennis M. Lanfear to Board Of Directors
8. Barr Announces Favorable Ruling in Yasmin(R) Patent Challenge
9. Vermillion Announces Effectiveness of Reverse Stock Split
10. Rosetta Genomics Announces Allowance of Two Additional microRNA Patents
11. ROBODOC(R) Announces Patent Cross Licensing Agreement With IBM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... days of demostrating Wisconsin's breakthroughs in biotechnology, the Wisconsin ... a discussion of what the state must do to attract ... Wisconsin has made in research, but explained without capital they ... moderator of the panel and president of the Wisconsin ...
... acquire AccuImage Diagnostic Corp. to expand its ... announced on Wednesday. , ,Merge eFilm, the business name ... with the San Francisco-based company in first-quarter 2005. , ... includes three-dimensional visualization tools that can be used for ...
... Milwaukee Metavante Corp. said it ... , which makes software that handles bank transactions and ... Marshall & Isley Corp, said in October that ... the software company into a wholly owned subsidiary. The ...
Cached Biology Technology:Out-of-state VCs offer advice on biotech investments 2Out-of-state VCs offer advice on biotech investments 3
(Date:11/18/2014)... Nov. 18, 2014  The Secure Identity & ... today jointly announce the formation of The Airport ... its Identity and Biometric Entry and Exit ... received official support from BORDERPOL, the international non-profit ... and provide expertise regarding border security, traveler and ...
(Date:11/15/2014)... 13, 2014  While we may still be a few ... in "Star Trek" to gain instant access to all that ... with smartphones and tablets for monitoring and measuring our health ... This may seem a tad Orwellian to some, but a ... of these technological opportunities into their healthcare regime. ...
(Date:11/7/2014)... Debra Auguste, associate professor, biomedical engineering, in the ... of New York, have identified a molecule that ... the most aggressive forms of breast cancer. , ... mortality rate owing to aggressive proliferation and metastasis ... Professor Auguste,s team, discovered the overexpression of intercellular ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... to put a price tag on the natural world? A ... rise of a new concept ecosystem services to ... Nature. Academic Dr Marion Potschin, of the University,s Centre ... who have been investigating the ethical considerations of this new ...
... . , Biopesticides containing beneficial fungi are ... Department of Agriculture (USDA) scientists have shown a liquid ... "liquid culture fermentation," offers several benefits, including lower material ... fungi, including Isaria or Metarhizium , ...
... CALGARY Researchers in Calgary have launched the first gene therapy ... enzyme deficiency that can shorten the lifespan of people who have ... first remove a quantity of stem cells from a Fabry patient,s ... inserted into the stem cells using a specially engineered virus. During ...
Cached Biology News:Valuing nature is not enough 2New, cost-cutting approach to formulating pest-killing fungi 2Canada launches first gene therapy trial for Fabry disease 2Canada launches first gene therapy trial for Fabry disease 3
...
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
... l-[35S]in vitro cell labeling mix, ... *Aqueous solution stabilized with 0.1% ... pyridine 3,4-dicarboxylic acid. *Amino acid ... labeling containing l-[35S]Methionine and l-[35S]Cysteine. ...
...
Biology Products: